• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in Patients With Cancer.

作者信息

Piazza Gregory

机构信息

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

JACC Case Rep. 2024 Nov 20;29(22 Suppl):102684. doi: 10.1016/j.jaccas.2024.102684.

DOI:10.1016/j.jaccas.2024.102684
PMID:39790114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11707376/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc0/11707376/f2edf0ac3e49/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc0/11707376/f2edf0ac3e49/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc0/11707376/f2edf0ac3e49/fx1.jpg

相似文献

1
Anticoagulation in Patients With Cancer.癌症患者的抗凝治疗
JACC Case Rep. 2024 Nov 20;29(22 Suppl):102684. doi: 10.1016/j.jaccas.2024.102684.
2
Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?我们是否应该重新将既往静脉血栓栓塞事件纳入房颤抗凝决策？
Am J Med. 2021 Jan;134(1):67-75.e5. doi: 10.1016/j.amjmed.2020.05.042. Epub 2020 Jul 4.
3
Atrial fibrillation and anticoagulation in patients with breast cancer.心房颤动和乳腺癌患者的抗凝治疗。
Scand Cardiovasc J. 2019 Oct;53(5):247-254. doi: 10.1080/14017431.2019.1638517. Epub 2019 Jul 9.
4
Apixaban for Treatment of Atrial Fibrillation and Venous Thromboembolism After Lung Transplantation.阿哌沙班用于肺移植术后房颤和静脉血栓栓塞的治疗。
Prog Transplant. 2023 Jun;33(2):175-181. doi: 10.1177/15269248231164173. Epub 2023 Mar 20.
5
Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy.心房颤动、血小板减少和血液恶性肿瘤患者的抗凝治疗。
J Thromb Thrombolysis. 2021 Aug;52(2):590-596. doi: 10.1007/s11239-021-02393-8. Epub 2021 Feb 1.
6
Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.CHA2DS2-VASc评分大于1的房颤患者在复律前口服抗凝治疗有益。
Int J Cardiol. 2016 Jul 15;215:360-3. doi: 10.1016/j.ijcard.2016.04.031. Epub 2016 Apr 11.
7
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.心房颤动卒中预防和肝硬化门静脉血栓形成及静脉血栓栓塞症抗凝治疗：来自 ISTH 的 SSC 指南。
J Thromb Haemost. 2024 Sep;22(9):2653-2669. doi: 10.1016/j.jtha.2024.05.023. Epub 2024 May 31.
8
[Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].[口服抗凝药预防非风湿性心房颤动血栓栓塞：适应证、有效性及风险]
Z Kardiol. 1993 Nov;82(11):667-73.
9
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
10
Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review.非瓣膜性心房颤动和静脉血栓栓塞症患者的抗凝风险评估：临床综述。
Vasc Med. 2019 Apr;24(2):141-152. doi: 10.1177/1358863X18819816. Epub 2019 Feb 12.

本文引用的文献

1
Outcomes and Discriminatory Accuracy of the CHADSVASc Score in Atrial Fibrillation and Cancer.房颤与癌症患者中CHADSVASc评分的结果及鉴别准确性
JACC Adv. 2023 Sep 16;2(8):100609. doi: 10.1016/j.jacadv.2023.100609. eCollection 2023 Oct.
2
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: State-of-the-Art Review.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的心血管毒性：最新综述
JACC CardioOncol. 2023 Oct 17;5(5):570-590. doi: 10.1016/j.jaccao.2023.09.002. eCollection 2023 Oct.
3
Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism.
癌症和静脉血栓栓塞症的发病率、发病机制和治疗的最新进展。
Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):824-831. doi: 10.1161/ATVBAHA.123.318779. Epub 2023 May 4.
4
Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study.依鲁替尼与口服抗凝剂联合治疗时的出血情况：一项基于人群的队列研究。
Am J Hematol. 2023 Mar;98(3):E49-E52. doi: 10.1002/ajh.26802. Epub 2022 Dec 7.
5
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: State-of-the-Art Review.癌症、心房颤动、动脉粥样硬化和血栓形成的共同病理生理学：最新综述
JACC CardioOncol. 2021 Nov 16;3(5):619-634. doi: 10.1016/j.jaccao.2021.08.011. eCollection 2021 Dec.
6
How to Manage Atrial Fibrillation Secondary to Ibrutinib.如何处理依鲁替尼继发的心房颤动
JACC CardioOncol. 2021 Mar 16;3(1):140-144. doi: 10.1016/j.jaccao.2020.11.016. eCollection 2021 Mar.
7
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.阿哌沙班治疗与癌症相关的静脉血栓栓塞症。
N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29.
8
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.我如何管理慢性淋巴细胞白血病患者对伊布替尼不耐受和并发症。
Blood. 2019 Mar 21;133(12):1298-1307. doi: 10.1182/blood-2018-11-846808. Epub 2019 Jan 14.
9
Epidemiology of cancer-associated venous thrombosis.癌症相关静脉血栓形成的流行病学。
Blood. 2013 Sep 5;122(10):1712-23. doi: 10.1182/blood-2013-04-460121. Epub 2013 Aug 1.